Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Eckman

Internal Medicine Fairlawn, OH Medical Doctor

NPI 1760482376 CMS profile 352846

150 Springside Dr Ste 320C, Fairlawn, OH 44333

Open in the dashboard

General payments

$10,468

792 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Eckman of Fairlawn, OH is reported in the CMS Open Payments database as having received $10,468 across 792 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $694 51
2024 General $724 41
2023 General $706 52
2022 General $1,974 141
2021 General $2,277 167
2020 General $2,159 168
2019 General $1,934 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Eckman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jeffrey Eckman were reported at $694. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jeffrey Eckman Internal Medicine median Middle half National median
2019 $1,934 $159 $48–$570 $163
2020 $2,159 $119 $33–$402 $114
2021 $2,277 $135 $37–$521 $132
2022 $1,974 $141 $42–$496 $149
2023 $706 $149 $45–$519 $160
2024 $724 $154 $47–$537 $164
2025 $694 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,413 184 payments
  2. AbbVie, Inc. $1,120 67 payments
  3. Pfizer Inc. $1,109 90 payments
  4. Amgen Inc. $1,019 68 payments
  5. AstraZeneca Pharmaceuticals LP $919 58 payments
  6. Lilly USA, LLC $739 55 payments
  7. GlaxoSmithKline, LLC. $680 53 payments
  8. Astellas Pharma US Inc $513 30 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $471 32 payments
  10. Amarin Pharma Inc. $278 19 payments
  11. Other $2,209 136 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,439 789 payments
  2. Education $28 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $772 132 payments
  2. ELIQUIS $522 46 payments
  3. Repatha $512 36 payments
  4. Prolia $496 32 payments
  5. EVENITY $472 30 payments
  6. FARXIGA $468 28 payments
  7. MYRBETRIQ $447 27 payments
  8. RYBELSUS $415 77 payments
  9. UBRELVY $404 24 payments
  10. TRULICITY $394 31 payments
  11. Other $9,688 664 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

9,437

Median for Internal Medicine: 777

Drug cost

$726,118

Median for Internal Medicine: $73,373

Branded share of claims

15.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 188 $220,496
Jardiance Empagliflozin Brand 64 $80,230
Trulicity Dulaglutide Brand 54 $75,281
Ozempic Semaglutide Brand 36 $34,235
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $32,464
Mounjaro Tirzepatide Brand 19 $31,177
Xarelto Rivaroxaban Brand 17 $25,200
Januvia Sitagliptin Phosphate Brand 15 $22,456
Myrbetriq Mirabegron Brand 27 $21,139
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $19,777

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$152,825

Of which drugs: $26,928

Medicare patients

282

Average age 75

Services billed

3,019

134 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 29%
Depression 28%
Chronic kidney disease 25%
Diabetes 22%
Atrial fibrillation 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 57 57 $16,584
Vaccine for influenza for injection into muscle 90653 Office 124 124 $9,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $69
$69 — —
NURTEC ODT
  • PFIZER INC. $57
$57 — —
VYEPTI
  • Lundbeck LLC $53
$53 — —
MOUNJARO
  • Lilly USA, LLC $52
$52 19 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $42
$42 64 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

792 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record